1 / 5

Break-out Group B

Break-out Group B. #5: Formaldehyde #12: IEUBK/Pb #26: Acrylamide Recommended all go forward (with funding considerations). Group B Participants. Nathalie Foronda (NZ) Kip Haney (TCEQ): Chair Lindsey Jones (TCEQ): Ass’t rapporteur Jerry Merski (Altria Client Services) Martha Moore (NCTR)

idalia
Download Presentation

Break-out Group B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Break-out Group B • #5: Formaldehyde • #12: IEUBK/Pb • #26: Acrylamide • Recommended all go forward (with funding considerations) DRAFT ARA Workshop I

  2. Group B Participants Nathalie Foronda (NZ) Kip Haney (TCEQ): Chair Lindsey Jones (TCEQ): Ass’t rapporteur Jerry Merski (Altria Client Services) Martha Moore (NCTR) Lynn Pottenger (Dow): Rapporteur Bob Tardiff (Sapphire) Kimberly Wise (API) Tong Zhou (FDA) [Harvey Clewell] [Thomas Dydek] [Suneeta Mahagaokar] DRAFT ARA Workshop I

  3. #5: Formaldehyde • Problem Formulation: HPV chemical with widely dispersive exposure: inhalation exposure focused on health-based risk estimates for toxicity/cancer (rats-nasal tumors; humans-respiratory tract tumors) • Methodology: Highly developed/detailed MOA (Pathophysiology process: cytotoxicity/cell proliferation-regeneration/hyperplasia/tumors), applies BBDR approach to quantify risk (integrates broad amount of data: cell proliferation rates, mutation rates, cross-links, etc.); need to incorporate genomic data & oncogene/tumor suppressor gene mutation data on p53/K-ras; Could address the following issues: • includes endogenous/background exposure and background processes; • address uncertainty and variability issues; • cross-species extrapolation (rats to humans); • test low-dose linearity proposal of SB; • incorporation of chemical-specific data; • address how much data is enough to depart from default. • Team: The Hamner/EPA folk plus Bruce Allen; Biologist: Barb Parsons, NCTR( ?), LHP (?); pathologist/cancer expertise (?); regulatory: Kip Chaney (TCEQ), EPA/IRIS Chemical Mgr (?); [Exposure expert (to address human exposure?)] DRAFT ARA Workshop I

  4. #12: IEUBK & Pb • Problem Formulation: Predict blood level in children exposed by various media (air, soil, food, etc.); (Literature review: Determine if current ‘level of concern’ (0.48 mmole/L) is appropriate); [this model can be used to evaluate soil clean-up targets] • Methodology: IEUBK model (both child and adult versions exist), developed specifically for lead, is actively used by USEPA & states: translates environmental sources of lead exposure into internal dose (blood lead level); could address the following issues: • incorporates background exposure in model predictions of dose-metrics (SB issue); • assess variability in exposure using distributions (e.g., dietary, water) (SB issue); • (lit review may help address low-dose linearity issue; SB issue) • Team: NZ Ministry of Health: Toxicology (N. Foronda); Public Health Physician (D. Read); Massey U. Epidemiologist (B. Borman); Modeller (TBD?) DRAFT ARA Workshop I

  5. #26: Acrylamide • Problem Formulation: HPV chemical with widely dispersive exposure, including diet: focus on oral exposure and developing MOA-based health-based risk estimates for cancer (rats- thyroid [& other] tumors; mouse-skin & lung tumors; humans-no specific target; epi data negative) • Methodology: Develop MOA approach based on WOE, based on acrylamide and its metabolite glycidamide; apply PBPK and BBDR approaches to understand the shape of the low dose dose-response curve; eventually use to quantify low dose risk; consider & incorporate new data from NCTR bioassays & MOA data (plan to use exposure characterized by JECFA); Could address the following issues: • includes endogenous/background exposure and background processes (mutation); • address uncertainty and variability issues; • cross-species extrapolation (rats and mice to humans); • test low-dose linearity proposal of SB; • incorporation of chemical-specific data (lots of new data); • application of MOA based on WOE; • address how much data is enough to depart from default. • Timeframe:Target completion in timeframe (may be challenge given new data & differing views) • Team:Bob Tardiff (Sapphire); M. Leigh Carson (Sapphire); Martha Moore (NCTR); Fred Beland (NCTR); Dan Doerge (NCTR); John Young (ret. NCTR); Lynne Haber (TERA);Errol Zeiger (consultant); David Gaylor (consultant); Sarah Henry (CFSAN) (?); Tong Zhou (FDA); TCEQ or other state rep? DRAFT ARA Workshop I

More Related